Top of the Street: Elisa, Burberry, Astrazeneca

Elisa Oyj

06/11/2024 14:17

A round-up of notable broker activity this morning from Europe's
top-ranked* analysts:
    
    ** Barclays upgrades Finnish telecoms group Elisa  ELISA.HE 
to "overweight" from "underweight" on expectations of solid
service revenue growth from upselling in a Finnish market viewed
as the strongest in Europe
    ** Berenberg raises Swiss semiconductor and vacuum solutions
company Inficon Holding  IFCN.S  to "buy" from "hold", saying
that recent share price correction provides a good entry point
into "a high-quality company that is well positioned for a
market recovery in 2025"
    ** Broker cuts British medical equipment maker Smith +
Nephew  SN.L  to "hold" from "buy" citing less clear recovery
path after a disappointing Q3, with headwinds in China leading
to guidance downgrades for 2024 and 2025
    ** RBC upgrades Burberry  BRBY.L  to "outperform" from
"sector perform" with a Speculative Risk qualifier as it is
potentially an acquisition target for Moncler  MONC.MI  or other
industry players
    ** Deutsche Bank cuts Astrazeneca  AZN.L  to "sell" from
"hold," as the company's "challenging" update for key next-gen
lung cancer pipeline asset datopotamab raised further material
questions over the asset and concerns on the potential 2025
guidance outlook
    
    (*Analyst rankings from Thomson Reuters StarMine. The scale
is from 1-star to 5-star with 5 being the best. Analysts are
ranked on earnings accuracy as well as relative performance of
recommendations over trailing 12-month & 24-month periods.)


 (Reporting by Tiago Brandao and Olivier Cherfan)
 ((Tiago.Brandao@thomsonreuters.com;
olivier.cherfan@thomsonreuters.com))